SYMATESE

SYMATESE, the French leader in tissue regeneration science, is undergoing a global expansion phase, building on 27 years of therapeutic and aesthetic innovation. The company stands out for its unique approach of translating its significant medical advances into cutting-edge aesthetic solutions, giving it a major competitive advantage. With its unique expertise, SYMATESE has established prestigious collaborations with global leaders such as L'Oréal, Evolus, Galderma, Nordic Pharma and Zimmer. These partnerships demonstrate the recognition of SYMATESE's expertise and strengthen its position in the international market. The company plans a significant expansion with the launch of ESTYME® and EVOLYSSE™ in the United States as early as April 2025 and very soon in Europe, followed by expansion into China and Brazil in 2026. SYMATESE has built a reputation for excellence in the field of tissue regeneration, with solutions that improve the lives of thousands of patients worldwide. From treatments for burn victims to post-skin cancer reconstruction, to innovative solutions for osteoarthritis or dry eye, SYMATESE is committed to pushing the boundaries of regenerative medicine. This therapeutic expertise is the foundation of his advances in aesthetic medicine. COLD-X TECHNOLOGY® by SYMATESE®, for example, redefines hyaluronic acid injectables by preserving natural hyaluronic acid to deliver superior performance. Similarly, ESTYME® MATRIX breast implants, based on PRYME® TECHNOLOGY by SYMATESE, incorporate a digital predictive model for increased safety and longevity. SYMATESE stands out for its capital independence and integrated approach to production. The company finances its own investments and controls the entire production chain, from the raw material to the final implant. The credo of the company and its managers, "the patient before the business", guides all decisions, with an extremely high level of security requirements.